Dissemination (Spotlight)

Patients with tardive dyskinesia being treated with vesicular monoamine transporter 2 inhibitors may see improvement in well-being along with TD symptoms.

Between 20% and 30% of patients with schizophrenia (SCZ)—and up to 50% patients with SCZ older than 50—develop tardive dyskinesia (TD), according to a study published in Genes & Genomics.

An uptick in biomarker testing for non-small cell lung cancer (NSCLC) over the past decade indicates an ongoing trend toward personalization of treatment choices.

First-line treatment that aligns with the results of biomarker testing and treatment guidelines is linked with better survival outcomes in patients with advanced or metastatic NSCLC.

Biomarker testing in non-small cell lung cancer informs therapeutic decisions at all stages of...

Comprehensive biomarker testing of patients with non-small lung cancer (NSCLC) is a critical part...

Biomarker testing is crucial for managing non-small cell lung cancer (NSCLC), with plasma-based...

Researchers conducted a study to investigate the experiences of patients and clinicians regarding...

A study aimed to enhance comprehensive biomarker testing for patients with metastatic...

A study aimed to analyze changes in biomarker testing among patients with metastatic non-small...

The following is a summary of “Role of tumor density in predicting significant cancer on targeted...

The following is a summary of “Clinical and treatment characteristics of secondary bladder...

Scientific knowledge of tardive dyskinesia (TD) over the past five decades will prove useful for...

Assessing the benefits and drawbacks of telehealth for tardive dyskinesia exams is critical as...

The following is the summary of “A genome-wide association study of chronic spontaneous urticaria...

The following is the summary of “Consecutive injections of low-dose interleukin-2 improve symptoms...

The following is the summary of “Most Patients With Autoimmune Chronic Spontaneous Urticaria Also...